Publicacións en colaboración con investigadores/as de University Hospital of Geneva (62)

2024

  1. Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows

    Endocrine Reviews, Vol. 45, Núm. 5, pp. 625-654

  2. Correction to: EANM perspectives for CZT SPECT in brain applications (European Journal of Nuclear Medicine and Molecular Imaging, (2024), 51, 12, (3680-3684), 10.1007/s00259-024-06788-6)

    European Journal of Nuclear Medicine and Molecular Imaging

  3. Correction: Vitamin D status and supplementation before and after Bariatric Surgery: Recommendations based on a systematic review and meta‑analysis (Reviews in Endocrine and Metabolic Disorders, (2024), 25, 2, (447-448), 10.1007/s11154-023-09837-x)

    Reviews in Endocrine and Metabolic Disorders

  4. EANM perspectives for CZT SPECT in brain applications

    European Journal of Nuclear Medicine and Molecular Imaging

  5. Epidemiological and Clinical Insights into the Enterovirus D68 Upsurge in Europe 2021-2022 and Emergence of Novel B3-Derived Lineages, ENPEN Multicentre Study

    Journal of Infectious Diseases, Vol. 230, Núm. 4, pp. e917-e928

  6. Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies

    Joint Bone Spine, Vol. 91, Núm. 2

  7. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

    The Journal of rheumatology, Vol. 51, Núm. 4, pp. 378-389

2023

  1. Diminishing benefits of urban living for children and adolescents’ growth and development

    Nature, Vol. 615, Núm. 7954, pp. 874-883

  2. One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment

    Journal of Rheumatology, Vol. 50, Núm. 8, pp. 1009-1019

  3. Vitamin D status and supplementation before and after Bariatric Surgery: Recommendations based on a systematic review and meta-analysis

    Reviews in Endocrine and Metabolic Disorders, Vol. 24, Núm. 6, pp. 1011-1029

2022

  1. After JAK inhibitor failure: To cycle or to switch, that is the question - Data from the JAK-pot collaboration of registries

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 2, pp. 175-181

  2. Author Correction: Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease (Nature Communications, (2020), 11, 1, (995), 10.1038/s41467-019-14275-y)

    Nature Communications

  3. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 10, pp. 1358-1366

  4. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response

    Rheumatology (Oxford, England), Vol. 61, Núm. 9, pp. 3799-3807

  5. Features of Mild-to-Moderate COVID-19 Patients With Dysphonia

    Journal of Voice, Vol. 36, Núm. 2, pp. 249-255

  6. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

    Arthritis Care and Research, Vol. 74, Núm. 7, pp. 1205-1218

  7. Regeneration of Craniofacial Bone Induced by Periosteal Pumping

    Tissue Engineering - Part C: Methods, Vol. 28, Núm. 2, pp. 61-72

  8. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis

    Rheumatology (Oxford, England), Vol. 61, Núm. 12, pp. 4741-4751

2021

  1. ACE2 & TMPRSS2 Expressions in Head & Neck Tissues: A Systematic Review

    Head and Neck Pathology, Vol. 15, Núm. 1, pp. 225-235

  2. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 11, pp. 1410-1418